Movement Alert｜GENFLEET-B Intraday Decline 5.12%, Competitor Revolution Medicines RAS Inhibitor NDA Accepted by FDA Sparks Competition Concerns

Market Focus07-28

On July 28, GENFLEET-B declined 5.12% in regular trading, trading at HK$31.54/share, with turnover of HK$10.16 million.

On the news front, competitor Revolution Medicines announced that its oral RAS inhibitor daraxonrasib's New Drug Application (NDA) has been accepted by the FDA, based on data from its pivotal Phase III study. GENFLEET-B's core product GFH375 is also a KRAS G12D inhibitor targeting the same mechanism. The competitor's advancement to regulatory review ahead of GENFLEET-B poses direct pressure on the company's best-in-class positioning for its pipeline.

Daraxonrasib is a pan-RAS inhibitor that has demonstrated historic survival benefits in second-line pancreatic ductal adenocarcinoma (PDAC) and positive early clinical results in first-line PDAC treatment. GENFLEET-B's GFH375, while having received two Breakthrough Therapy Designations in China and Fast Track Designation from the FDA, remains in Phase III clinical trials. The competitive landscape intensification raises concerns about GENFLEET-B's timeline to market and its differentiation against an approved therapy.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1178553338?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-28 10:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1178553338","market":"hk","top_or_hot":-1,"title":"Movement Alert｜GENFLEET-B Intraday Decline 5.12%, Competitor Revolution Medicines RAS Inhibitor NDA Accepted by FDA Sparks Competition Concerns","media":"Market Focus","content":"<p><p>On July 28, GENFLEET-B declined 5.12% in regular trading, trading at HK$31.54/share, with turnover of HK$10.16 million.</p><p>On the news front, competitor Revolution Medicines announced that its oral RAS inhibitor daraxonrasib's New Drug Application (NDA) has been accepted by the FDA, based on data from its pivotal Phase III study. GENFLEET-B's core product GFH375 is also a KRAS G12D inhibitor targeting the same mechanism. The competitor's advancement to regulatory review ahead of GENFLEET-B poses direct pressure on the company's best-in-class positioning for its pipeline.</p><p>Daraxonrasib is a pan-RAS inhibitor that has demonstrated historic survival benefits in second-line pancreatic ductal adenocarcinoma (PDAC) and positive early clinical results in first-line PDAC treatment. GENFLEET-B's GFH375, while having received two Breakthrough Therapy Designations in China and Fast Track Designation from the FDA, remains in Phase III clinical trials. The competitive landscape intensification raises concerns about GENFLEET-B's timeline to market and its differentiation against an approved therapy.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜GENFLEET-B Intraday Decline 5.12%, Competitor Revolution Medicines RAS Inhibitor NDA Accepted by FDA Sparks Competition Concerns</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜GENFLEET-B Intraday Decline 5.12%, Competitor Revolution Medicines RAS Inhibitor NDA Accepted by FDA Sparks Competition Concerns\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-28 10:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 28, GENFLEET-B declined 5.12% in regular trading, trading at HK$31.54/share, with turnover of HK$10.16 million.</p><p>On the news front, competitor Revolution Medicines announced that its oral RAS inhibitor daraxonrasib's New Drug Application (NDA) has been accepted by the FDA, based on data from its pivotal Phase III study. GENFLEET-B's core product GFH375 is also a KRAS G12D inhibitor targeting the same mechanism. The competitor's advancement to regulatory review ahead of GENFLEET-B poses direct pressure on the company's best-in-class positioning for its pipeline.</p><p>Daraxonrasib is a pan-RAS inhibitor that has demonstrated historic survival benefits in second-line pancreatic ductal adenocarcinoma (PDAC) and positive early clinical results in first-line PDAC treatment. GENFLEET-B's GFH375, while having received two Breakthrough Therapy Designations in China and Fast Track Designation from the FDA, remains in Phase III clinical trials. The competitive landscape intensification raises concerns about GENFLEET-B's timeline to market and its differentiation against an approved therapy.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02595","symbol_name":"劲方医药-B","start_time":0,"source_url":"","article_id":"1178553338","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1178553338","pubTimestamp":1785204674,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 28, GENFLEET-B declined 5.12% in regular trading, trading at HK$31.54/share, with turnover of HK$10.16 million.On the news front, competitor Revolution Medicines announced that its oral RAS...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02595":"劲方医药-B"},"translate_title":"动向提醒|GENFLEET-B盘中跌5.12%，竞争对手Revolution Medicines RAS抑制剂NDA获FDA受理引发竞争担忧","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02595":1},"content_text":"On July 28, GENFLEET-B declined 5.12% in regular trading, trading at HK$31.54/share, with turnover of HK$10.16 million.On the news front, competitor Revolution Medicines announced that its oral RAS inhibitor daraxonrasib's New Drug Application (NDA) has been accepted by the FDA, based on data from its pivotal Phase III study. GENFLEET-B's core product GFH375 is also a KRAS G12D inhibitor targeting the same mechanism. The competitor's advancement to regulatory review ahead of GENFLEET-B poses direct pressure on the company's best-in-class positioning for its pipeline.Daraxonrasib is a pan-RAS inhibitor that has demonstrated historic survival benefits in second-line pancreatic ductal adenocarcinoma (PDAC) and positive early clinical results in first-line PDAC treatment. GENFLEET-B's GFH375, while having received two Breakthrough Therapy Designations in China and Fast Track Designation from the FDA, remains in Phase III clinical trials. The competitive landscape intensification raises concerns about GENFLEET-B's timeline to market and its differentiation against an approved therapy.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1178553338","isCrawlerRequest":true}